02.10.25 Web Release
Innospera Pharma receives the “Investment of the Year” Award at Anges Québec 2025 Annual Meeting
MONTREAL, Canada — October 2, 2025 — Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotech developing small-molecule GPCR modulators for chronic and fibrotic diseases, today announced that it has been granted the “Investment of the Year” Award by Anges Québec, Canada’s largest angel investors group.
“We all feel honoured by this prestigious award, a symbol of trust and commitment reflecting the importance of angel investment in supporting biotech innovation in Quebec,” said Pierre Laurin, Executive Chairman of the board of Innospera Pharma. “A successful biotech flourishes when strong science meets significant market opportunities: investors from Anges Québec acknowldeged our vision and we are grateful for that”.
About Anges Québec
As Canada’s largest angel investors group, Anges Québec has been supporting passionate and innovative entrepreneurs for 15 years. With over 200 members from diverse backgrounds who have collectively invested nearly $148 million in more than 200 Quebec tech companies, in partnership with the AQC Capital fund, Anges Québec is proud to play a leading role in the venture capital industry in Quebec by actively supporting local innovation.
About Innospera
Innospera Pharma is a private biotech developing small-molecule GPCR modulators for chronic and fibrotic diseases. Lead asset ING-006, a next-generation GPR84 modulator, has shown strong anti-fibrotic activity in gold-standard preclinical models. A 20–40x more potent analog of PBI-4050 (three Phase 2a trials; FDA-approved Phase 3 IPF protocol), ING-006 pairs a superior pharmacological profile with an anticipated wide safety margin and tolerability. The Company’s pipeline includes additional GPCR modulators targeting cardiometabolic and other chronic conditions.
$ $ $
Contact
Pierre Laurin, BPharm, MSc
Executive Chairman
Innospera Pharma inc